Clinical Trial Update: MIBG for Refractory Neuroblastoma and Pheochromocytoma [NA]

View source ↗

Summary

The clinical trial evaluating MIBG for relapsed neuroblastoma and metastatic pheochromocytoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Pheochromocytoma

Drugs mentioned

• MIBG (metaiodobenzylguanidine)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Relapsed Neuroblastoma, Metastatic Pheochromocytoma | NA | Status: COMPLETED